Abstract
Abnormal bleeding is sometimes observed in patients with immunoglobulin light chain (AL) amyloidosis. Although several theories have been proposed regarding the pathological causes of the bleeding tendency in AL amyloidosis, many lacked sufficient evidence and full consensus. We conducted a retrospective survey at a single institution to assess bleeding manifestations, methods for evaluating hematological abnormalities, and treatments for bleeding in patients with systemic AL amyloidosis over the past 13 years. The participants were 10 men and 14 women, aged 39–84 years (mean 65 years). The prevalence of bleeding was 29%. Prolonged prothrombin time (PT), elevated plasmin–α2-antiplasmin complex, and factor X deficiency were distinctive to the bleeding group. Two case studies showed that tranexamic acid was effective for treating this hematological condition. However, two patients with normal PT and activated partial thromboplastin time (APTT) also had a bleeding manifestation. The rates of administration of coagulation and fibrinolytic tests were relatively low in the non-bleeding group. Therefore, a close investigation concerning coagulation and fibrinolysis should be performed in every patient with AL amyloidosis regardless of the PT/APTT values. A more careful, comprehensive, and large-scale study is required to reinforce these findings.
Similar content being viewed by others
References
Vaxman I, Gertz M. Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol. 2019;141(2):93–106.
Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91(9):947–56.
Iida S, Shimazaki C, Abe M, Nakaseko C. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma. Int J Hematol. 2019;109(6):633–40.
Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol. 1993;11(5):914–20.
Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, et al. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013;88(5):375–8.
Merlini G, Palladini G. Light chain amyloidosis: the heart of the problem. Haematologica. 2013;98(10):1492–5.
Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885–7.
Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med. 2014;53(5):403–12.
Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110(2):454–60.
Gertz MA, Kyle RA. Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med. 1988;85(1):73–80.
Gamba G, Montani N, Anesi E, Palladini G, Capezzera M, Soldavini E, et al. Clotting alterations in primary systemic amyloidosis. Haematologica. 2000;85(3):289–92.
Uchiba M, Imamura T, Hata H, Tatetsu H, Yonemura Y, Ueda M, et al. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid. 2009;16(2):89–93.
Shimazaki C, Hata H, Iida S, Ueda M, Katoh N, Sekijima Y, et al. Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan. Intern Med. 2018;57(2):181–7.
Furie B, Voo L, McAdam KP, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med. 1981;304(14):827–30.
Gastineau DA, Gertz MA, Daniels TM, Kyle RA, Bowie EJ. Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality. Blood. 1991;77(12):2637–40.
Liebman H, Chinowsky M, Valdin J, Kenoyer G, Feinstein D. Increased fibrinolysis and amyloidosis. Arch Intern Med. 1983;143(4):678–82.
Sucker C, Hetzel GR, Grabensee B, Stockschlaeder M, Scharf RE. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006;47(6):947–55.
Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O'Hara C, et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol. 2007;82(5):363–7.
Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA. 1983;249(10):1322–4.
Hoshino Y, Hatake K, Muroi K, Tsunoda S, Suzuki T, Miwa A. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med. 1993;32(11):879–81.
Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 2010;85(3):171–3.
Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–18.
NCCN Clinical Practice Guidelines in Oncology. Systemic light chain amyloidosis Version 1. Plymouth Meeting (PA): National Comprehensive Cancer Network. 2019; Available from: https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf. Accessed 20 July 2019
Amyloidosis Research Committee, Guidelines for Clinical Practice of Amyloidosis. Fukui (Japan): executive office of amyloidosis research committee. 2010; Available from: https://amyloidosis-research-committee.jp/guideline/. Accessed 20 July 2019 (Japanese)
Suga N, Miura N, Kitagawa W, Morita H, Banno S, Imai H. Differential diagnosis of localized and systemic amyloidosis based on coagulation and fibrinolysis parameters. Amyloid. 2012;19(2):61–5.
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–28.
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–32.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95.
Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (easy R) for medical statistics. Bone Marrow Transplant. 2013;48(8):452–8.
Ishiguro K, Hayashi T, Yokoyama Y, Aoki Y, Onodera K, Ikeda H, et al. Elevation of plasmin-α2-plasmin inhibitor complex predicts the diagnosis of systemic AL amyloidosis in patients with monoclonal protein. Intern Med. 2018;57(6):783–8.
Pryzdial EL, Lavigne N, Dupuis N, Kessler GE. Plasmin converts factor X from coagulation zymogen to fibrinolysis cofactor. J Biol Chem. 1999;274(13):8500–5.
Grundy JE, Lavigne N, Hirama T, MacKenzie CR, Pryzdial EL. Binding of plasminogen and tissue plasminogen activator to plasmin-modulated factor X and factor Xa. Biochemistry. 2001;40(21):6293–302.
Talbot K, Meixner SC, Pryzdial EL. Proteolytic modulation of factor Xa-antithrombin complex enhances fibrinolysis in plasma. Biochim Biophys Acta. 2013;1834(6):989–95.
van Rijn RS, Verdonck LF. An unusual cause of bleeding. Lancet. 2001;358(9291):1424.
Colucci G, Alberio L, Jahns M, Keller P, Steiner S, Rüsges-Wolter I, et al. Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired alpha2-antiplasmin deficiency associated with AL amyloidosis. Thromb Haemost. 2009;102(6):1285–7.
McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72(5):585–617.
Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018;132(26):2775–7.
Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, et al. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood Cancer J. 2017;7(2):e537.
Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817–22.
Acknowledgements
This study was supported in part by a grant-in-aid from the Japanese Ministry of Health, Labour, and Welfare (to A.I.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
H. Takamatsu reports grants and personal fees from Celgene, Bristol–Myers Squibb and Ono pharmaceutical, grants from CSL Behring and SRL, and personal fees from Bristol–Myers Squibb, Janssen Pharmaceutical, Sanofi, Takeda Pharmaceutical, Fujimoto Pharmaceutical, Becton, Dickinson and Company, outside the submitted work. The other authors report no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Arahata, M., Takamatsu, H., Morishita, E. et al. Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid. Int J Hematol 111, 550–558 (2020). https://doi.org/10.1007/s12185-019-02811-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-019-02811-x